[Cyclosporin A in severe aplastic anemia in children].
Severe aplastic anemia should be treated with bone marrow transplantation if possible. Various clinical and experimental data support the view that the major pathogenetic defect in SAA is a dysregulated cellular immune response which in turn has a negative effect upon hematopoiesis. Therefore a large percentage of patients react favorably to treatment with immunosuppressive agents as antithymocyte globulin and high-dose methylprednisolone. Data concerning the efficiency of Cyclosporine A treatment are limited until now. We present in this report our own experience with Cyclosporine A treatment in three children with severe aplastic anemia who lack a bone marrow donor. Included is also a review of the present therapeutic possibilities.
Lackner
H
H
Universitäts-Kinderklinik, Graz.
Urban
C
C
Kaulfersch
W
W
Slavc
I
I
Gamillscheg
A
A
Hauer
C
C
D000293:Adolescent; D000741:Anemia, Aplastic / Q000188:drug therapy*; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D003524:Cyclosporins / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004906:Erythrocyte Count / Q000187:drug effects; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D007223:Infant; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D012156:Reticulocytes / Q000187:drug effects
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D008775:Methylprednisolone
Cyclosporin A bei schwerer aplastischer Anämie im Kindesalter.